Octanate (Human Coagulation Factor Viii)

Octanate is used to manage bleeding disorders that involve factor VIII deficiency.

• Hemophilia A (congenital): provides factor VIII replacement to prevent or control bleeding episodes.
• Acquired hemophilia A: supplies exogenous factor VIII to restore clotting function.
• Peri‑operative management: ensures adequate haemostasis during surgery or invasive procedures.
• Prophylaxis in severe hemophilia A: maintains trough factor levels to reduce spontaneous bleeds.

• Octanate supplies functional human factor VIII, a cofactor in the intrinsic pathway of the coagulation cascade. By binding to activated factor IX, it facilitates the conversion of factor X to Xa, leading to thrombin generation and fibrin clot formation, thereby correcting the clotting defect in factor VIII‑deficient patients.

Octanate may be associated with adverse reactions following administration.

Common Side Effects

• Headache: mild to moderate intensity.
• Fever: transient elevation of body temperature.
• Infusion site reactions: redness, swelling, or pain.
• Nausea: occasional gastrointestinal discomfort.
• Mild rash: localized skin irritation.

Serious or Rare Side Effects

• Development of inhibitors: neutralising antibodies against factor VIII.
• Anaphylactic reaction: severe allergic response requiring emergency care.
• Thromboembolic events: clot formation in veins or arteries.
• Viral transmission: risk of blood‑borne pathogen transmission despite viral inactivation.

Octanate should be used with careful clinical monitoring.

• Allergy assessment: evaluate for known hypersensitivity to plasma‑derived products.
• Inhibitor testing: regularly assess for anti‑factor VIII antibodies.
• Surgical planning: coordinate dosing with surgical teams to ensure haemostasis.
• Concomitant anticoagulants: adjust therapy to avoid excessive bleeding.
• Pediatric use: dose and monitoring must be individualized for children.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octanate may interact with other agents affecting coagulation.

Major Interactions (Avoid)

• Bypassing agents (e.g., activated prothrombin complex concentrates): may increase thrombotic risk.
• High‑dose vitamin K antagonists: can exacerbate bleeding if not managed.

Moderate Interactions (Monitor Closely)

• Antifibrinolytics (e.g., tranexamic acid): may enhance clot stability, monitor for thrombosis.
• Immunosuppressants: could affect inhibitor development.
• Other plasma‑derived products: assess cumulative factor load.